Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in moderate to severe persistent asthma
NCT00141791Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2005
- Primary completion
- Jul 2006
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Etanercept with Placebo (2 arms). Primary endpoint: Forced Expiratory Volume in 1 second at 12 weeks. Started May 2005; status: completed.
02
Drugs
etanercept
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00141791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141791.